Author + information
- Gregg C. Fonarowa,b,
- Nancy Alberta,b,
- Javed Butlera,b,
- J. Herb Pattersona,b,
- John Spertusa,b,
- Fredonia Williamsa,b,
- Stuart Turnera,b,
- Wing Chana,b,
- Carol Duffya,b,
- Adam DeVorea,b,
- Xiaojuan Mia,b,
- Laine Thomasa,b and
- Adrian Hernandeza,b
Background: Few data exist regarding contemporary care patterns for heart failure with reduced ejection fraction (HFrEF) in the outpatient setting. Change the Management of Patients with Heart Failure (CHAMP-HF) is a prospective cohort study designed to characterize current management of patients with chronic HFrEF in a national registry of outpatient practices.
Methods: Baseline patient characteristics, medications, care patterns, and patient-reported health status of patients diagnosed with HF and EF≤40% were collected. The use of therapies was analyzed overall and by age group, sex, and NYHA functional class.
Results: Patients (n=1278) had a median age of 68 (IQR 59-76) years, median EF of 30% (IQR 23-35), and NYHA distribution was Class I 10.5%, II 52.1%, III 30.3%, IV 2.8% from 92 practices (89.1% nonteaching). Use of ACEI/ARB was 57.4%, whereas ARNI use was 13.0%. Beta-blocker use was 82.6% (evidence-based only 68.2%), aldosterone antagonist 31.5%, and hydralazine/nitrate 4.6%. Only 1.1% of patients were treated with ivabradine. Use of guideline-recommended therapies by age, sex, and NYHA varied (Table).
Conclusions: These data are among the first to assess treatment in the outpatient setting since the availability of new therapies/release of the latest national HF guidelines and demonstrate variable uptake of new therapies among outpatient practices and differences in use by patient age, sex, and NYHA class.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1121-243
- 2017 American College of Cardiology Foundation